When a Supreme Court bench recently slammed a 1,000 per cent markup on life-saving cancer drugs — where a chemotherapy injection supplied to retailers for Rs 2,700 was stamped with an MRP of Rs 27,000 — it pulled no punches. Calling the practice “broad daylight dacoity” and asking the Centre, “Can you justify this loot?” the apex court voiced the helpless fury felt across millions of Indian households.
Following the judicial heat, trade margins on several anti-cancer formulations were capped at 30 per cent. The court went on to ask why this cap cannot be imposed on all other life-saving drugs as well and posted the case, for the central government’s response, to a short date.
Yet, as the nation turns its spotlight on price-gouging in oncology , a far more troubling structural question arises: Leave alone life-saving cancer therapies, why are even ordinary, everyday branded medicines—which have identical, vastly cheaper unbranded generic equivalents — persistently rejected by Indian consumers?
India runs…